Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach

Autor: Nea Pitulis, Theodoros Dimopoulos, Haralampos Katopodis, Dimitrios Karamanolakis, Michael Koutsilieris, Antonis Halapas, John Bogdanos, N Pissimissis, Effie Papageorgiou, Peter Dimopoulos, Antigone Sourla, Constantine Milathianakis, Peter Lembessis, Roxane Tenta
Rok vydání: 2006
Předmět:
Male
Oncology
Osteoclasts
Salvage therapy
Apoptosis
Dexamethasone
Gonadotropin-Releasing Hormone
Prostate cancer
Antineoplastic Combined Chemotherapy Protocols
Pharmacology (medical)
Prospective Studies
Orchiectomy
Growth Substances
Etoposide
Randomized Controlled Trials as Topic
Triptorelin Pamoate
Bone metastasis
General Medicine
Combined Modality Therapy
Neoplasm Proteins
Somatostatin
Receptors
Androgen
Androgens
Estramustine
medicine.symptom
medicine.medical_specialty
Neoplasms
Hormone-Dependent
Antineoplastic Agents
Hormonal
Combination therapy
medicine.drug_class
Bone Neoplasms
Adenocarcinoma
Peptides
Cyclic
Clinical Trials
Phase II as Topic
Internal medicine
Paracrine Communication
medicine
Humans
Bone pain
Salvage Therapy
Pharmacology
Osteoblasts
business.industry
Prostatic Neoplasms
Androgen Antagonists
medicine.disease
Androgen
Survival Analysis
Drug Resistance
Neoplasm
Leuprolide
business
Zdroj: Expert Opinion on Investigational Drugs. 15:795-804
ISSN: 1744-7658
1354-3784
DOI: 10.1517/13543784.15.7.795
Popis: The development of resistance to anticancer therapies is a major hurdle in preventing long-lasting clinical responses to conventional therapies in hormone-refractory prostate cancer. Herein, the molecular evidence documenting that bone metastasis microenvironment survival factors (mainly the paracrine growth hormone-independent, urokinase-type plasminogen activator-mediated increase of IGF-1 and the endocrine production of growth hormone-dependent IGF-1, mainly liver-derived IGF-1 production) produce an epigenetic form of prostate cancer cells that are resistant to proapoptotic therapies is reviewed. Consequently, the authors present the conceptual framework of a novel antibone microenvironment survival factor, mainly an anti-IGF-1 hormonal manipulation for androgen ablation refractory prostate cancer (a combination of conventional androgen ablation therapy [luteinising hormone-releasing hormone agonist-A or orchiectomy]) with dexamethasone plus somatostatin analogue, which yielded durable objective responses and major improvement of bone pain and performance status in stage D3 prostate cancer patients.
Databáze: OpenAIRE
Externí odkaz: